KR20160081164A - Skin external composition for anti-anging comprising compound K and picrionoside A - Google Patents

Abstract

The present invention relates to a cosmetic composition for anti-aging and, more particularly, to an anti-aging skin composition for external uses comprising compound K and picrionoside A as effective components. The anti-aging skin composition for external uses exhibits an antioxidative effect, and reduces skin wrinkles while enhancing skin elasticity.

Description

[0001] The present invention relates to a skin external composition for anti-aging comprising compound K and picronoside A,

The present invention relates to an anti-aging cosmetic composition, and more particularly, to an anti-aging cosmetic composition which contains an active ingredient of Compound K and picronoside A to exhibit an antioxidative effect and reduce skin wrinkles and increase skin elasticity ≪ / RTI >

Human skin is the primary protective membrane of the human body. It functions to protect the internal organs from external environmental stimuli such as changes in temperature and humidity, ultraviolet rays, and pollutants. Depending on various internal and external factors, It undergoes change. In other words, internally, secretion of various hormones that regulate metabolism is reduced, the function of immune cells and the activity of cells are lowered, and the biosynthesis of immune proteins and biocompatible proteins necessary for the living body is reduced, and ozone layer destruction As the content of ultraviolet rays reaching the surface of the sunlight increases and environmental pollution is further intensified, free radicals and active noxious oxygen are increased, so that the thickness of the skin decreases, the wrinkles increase, the elasticity decreases Skin color is grayish, skin troubles are frequent, spots, freckles and black spots are increased, bleeding is poor, skin tone is getting dark, and so on.

In order to prevent the change of the skin condition due to the intrinsic and extrinsic factors, and to maintain a healthy skin condition, physiologically active substances obtained from various known animals, plants, microorganisms and the like are added to cosmetics to improve the skin condition There has been effort for.

On the other hand, picrionoside A is a perennial plant belonging to the fern-tail gosarit family ( Asplenium Interface Variable Name Carcinoid derived from a portion of scolopendrium) (isolated from terpenoid) component, or chemically synthesized can also (Natural Product Sciences, 14 (4 ): 265-268 (2008)). As to the icaricide compound icaride II (icariside II), whitening activity is already known (International Patent Publication No. WO 2008/035918, published on Mar. 27, 2008). On the other hand, the research on picronoside A, which is an icarcyse-based compound, is insignificant, and notably remarkable research results have not been reported on the synergistic effect on the efficacy shown in relation to the improvement of skin condition and the combination with other ingredients .

Korean Patent Laid-Open No. 10-2012-0083943 (published on July 27, 2012) International Patent Publication No. WO 2008/035918 (published on Mar. 27, 2008)

Natural Product Sciences, 14 (4): 265-268 (2008)

The present invention provides a composition having excellent antioxidative and anti-aging effects, specifically promoting collagen synthesis, skin elasticity improvement effect and skin wrinkle-improving effect by using Compound K in combination with picronoside A .

In order to accomplish the above object, the present invention provides a compound K represented by the following formula 1: And a picronoside A represented by the following formula 2 as an active ingredient, wherein the compound K is contained in an amount of 0.002 to 1 wt% based on the total weight of the composition, and the picronoside A is a composition total Wherein the compound K is contained in an amount of 0.03 to 30 wt% based on the weight of the composition, and the content ratio of the compound K to the criconoside A is 1:25 to 1:50 in molar ratio.

The composition according to the present invention contains the compound K and picronoside A in combination, thereby exhibiting an excellent antioxidative effect even when the active ingredient is used at a low concentration and effectively preventing or improving skin aging.

The composition according to the present invention can prevent or improve skin aging by containing the compound K and picronoside A as an active ingredient.

The compound K used in the present invention is a compound having a structure of the following formula 1 and a molecular weight of 622.88.

[Chemical Formula 1]

The compound K used in the present invention may be extracted from plants or may be synthesized according to methods known in the art or commercially available ones may be used. Compound K can also be obtained from ginseng extract. The type of ginseng to be used at this time is not particularly limited, and ginseng, red ginseng, white ginseng, taegeuk ginseng and ginseng can be used. In addition, the ginseng extract is not only contained in the leached liquid obtained by leaching and transferring from ginseng but also contained in the concentrate obtained by partially or completely concentrating the leach solution or in the slump, premix, regular season, liquid extract and ginseng prepared by drying the concentrate again It contains all of the plant itself as well as chemicals that exert the main effect. Extracts from all parts of ginseng such as stem, root, leaf, flower, and fruit are available and are not limited to any particular part of the extract. Also, a known method can be used as a method of extracting the compound K from the ginseng extract.

Specifically, the compound K can be isolated from ginseng after preparing ginseng extract from water or an organic solvent by a method well known in the art. The organic solvent used in the present invention may be selected from the group consisting of ethanol, methanol, butanol, ether, ethyl acetate, chloroform and a mixed solvent of these organic solvents and water, preferably 80% ethanol. At this time, the extraction temperature is preferably 10 to 80 ° C, and the extraction can be performed for 3 to 24 hours. If the extraction temperature and the extraction time are exceeded, the extraction efficiency may be deteriorated or the component may be changed.

Pycryonoside A used in the present invention is a compound having a structure represented by the following formula (2), and has a molecular weight of 370. 4- [2,6,6-Trimethyl-4- (3,4,5-trihydroxy- 2-yloxy) -cyclohex-2-enyl] -but-3-en-2- one (4- [2,6,6-trimethyl- 4- , 4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy) -cyclohex-2-enyl] -but-3-en-2-one.

(2)

The composition of the present invention contains 0.002-1 wt% of compound K and 0.03-30 wt% of picronoside A based on the total weight of the composition based on in vitro and in vivo experiments. %, Preferably 0.004 to 0.25 wt% of compound K and 0.055 to 7.5 wt% of picronoside A based on the total weight of the composition. If the effective ingredient is below the above range, it is difficult to expect the efficacy and the effect of the above-mentioned ingredients, and even when the content is over the above range, the compound K and picronoside A are combined, .

Further, the composition of the present invention contains compound K and picronoside A at a molarity ratio of preferably 1:25 to 1:50.

The composition of the present invention provides excellent antioxidant power. Accordingly, the composition of the present invention can effectively prevent or improve extrinsic aging (i.e., photoaging), which is affected by active oxygen generated by external factors such as ultraviolet rays, tobacco smoke, and the like, Thereby reducing skin wrinkles and improving skin elasticity.

In addition, the composition of the present invention can promote the synthesis of collagen and skin regeneration.

The composition of the present invention may be formulated as an external preparation for skin, in particular as a cosmetic composition, and may be formulated containing a cosmetically or dermatologically acceptable medium or base. In addition, the composition of the present invention can be provided in all formulations suitable for topical application, for example, as a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing a water phase in an oil phase, a suspension, a microemulsion, Gels, powders, pastes, foams or aerosol compositions of the present invention may be provided in the form of microgranules or ionic (liposomes) and non-ionic follicular dispersants, solids, gels, powders, pastes, foams or aerosol compositions. Specifically, the composition of the present invention may be provided in the form of a cream, a skin, a lotion, a powder, an ointment, a spray or a cone stick. Compositions of such formulations may be prepared according to conventional methods in the art.

In addition, the composition of the present invention may contain a skin absorption promoting substance to increase the skin improving effect.

In addition, the composition according to the present invention may contain, in addition to the above-mentioned substances, other ingredients which can give a synergistic effect to the main effect, to the extent that the main effect is not impaired. The composition according to the present invention may further comprise a humectant, an emollient, an ultraviolet absorber, an antiseptic, a bactericide, an antioxidant, a pH adjuster, an organic or inorganic pigment, a perfume, a cold agent or a limiting agent. The compounding amount of the above components can be easily selected by a person skilled in the art within the range not impairing the object and effect of the present invention, and the amount thereof may be from 0.01 to 5% by weight, specifically from 0.01 to 3% by weight based on the total weight of the composition .

In addition, the composition of the present invention can be formulated as a pharmaceutical composition. When the composition according to the present invention is applied to medicines, it may be formulated into oral, parenteral or parenteral dosage forms in solid, semi-solid or liquid form by adding an inorganic or organic carrier compatible with the active ingredient used in the present invention , The pharmaceutical composition according to the present invention may be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously, and the like.

Examples of the formulations for oral administration include tablets, pills, granules, capsules, powders, fine granules, powders, emulsions, syrups and pellets. In addition, the formulations for parenteral administration include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like. The composition according to the present invention can be easily formulated into an active ingredient by carrying out the composition according to a conventional method. In this case, a surfactant, excipient, coloring agent, spice, preservative, stabilizer, buffer, suspending agent, have.

The dosage of the active ingredient of the pharmaceutical composition of the present invention will vary depending on the age, sex, body weight, pathological condition and severity of the subject to be treated, route of administration, or judgment of the prescriber. Determination of the appropriate dose based on these factors is well within the level of ordinary skill in the art and its daily dose is, for example, from 0.1 mg / kg / day to 100 mg / kg / day, more specifically from 5 mg / kg / day to 50 mg / / Day, but is not limited thereto.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for illustrating the present invention and that the scope of the present invention is not construed as being limited by these embodiments.

[Reference Example 1] Preparation of compound K

Compound K for testing the efficacy of the composition of the present invention was purchased from Ambo Research Institute (Korea).

[Reference Example 2] Preparation of picronoside A

The MeOH extract was obtained by sonication with MeOH, and the fractions were fractionated into n-hexane, CH ₂ Cl ₂ , n-BuOH and H ₂ O layers. One compound was separated from the CH ₂ Cl ₂ layer through Sephadex LH-20 and silica gel column chromatography. The fraction was separated from the n-BuOH layer by MCI-gel column chromatography (MCI- gel column chromatography, 100% H ₂ O-> 100% MeOH). 3.0 mg of picronoside A was obtained using HPLC (High-performance liquid chromatography, AcCN-H ₂ O = 19: 81, 2 ml / min, YMC J'sphere ODS-H80).

The thus obtained picronoside A was used in the following test.

[Referential Example 3] Preparation of Compound K standard solution

62.3 μg of Compound K of Reference Example 1 and 5 mL of distilled water were mixed to prepare 6 standard solutions of Compound K 20 μM. 5 μM, 4 μM, 2 μM, 1 μM and 0.1 μM compound K standard solutions were prepared by adding 15 mL, 20 mL, 45 mL, 95 mL and 995 mL of distilled water to five of the 20 μM standard solutions, respectively.

[Reference Example 4] Preparation of picronoside A standard solution

1850 占 퐂 of the picronoside A of Reference Example 2 and 5 ml of distilled water were mixed to prepare three 1000 占 피 standard solutions of picronoside A. 45 mL and 495 mL of distilled water were added to two of the prepared 1000 μM standard solutions, respectively, to prepare 100 μM and 10 μM picronoside A standard solutions.

[Test Example 1] Inhibitory effect on reactive oxygen species (ROS) production

Keratinocyte (cell line: HaCaT; available from ATCC) was cultured in a 24 well cell culture medium containing keratinocyte growth media (Clonetics, BioWhittacker, MD, USA) 5 x 10 ⁴ pieces were put into each well of the plate and adhered for 24 hours. After 16 hours, Compound K standard solutions (concentration: 20 μM, 5 μM, 4 μM, 2 μM, 1 μM and 0.1 μM) of Reference Example 3 and the picronoside A standard solution (concentration: 1000 [mu] M, 100 [mu] M and 10 [mu] M). For comparison, the control group did not treat the test substance. After 2 hours, the culture solution was removed, and 100 μl of phosphate buffered saline (PBS) was added to each well. The keratinocytes were irradiated with ultraviolet rays of 30 mJ / cm 2 using an ultraviolet B (UVB) lamp (Model: K5T8, UVB 15W, Sankyo Dennki, Japan), and PBS was removed. Was added. The test substance was treated again and the amount of reactive oxygen species (ROS) increased by ultraviolet stimulation was determined at predetermined time intervals. At this time, for comparison, the amounts of active oxygen species were measured without treatment of the test substance (untreated), with no ultraviolet stimulation, and with ultraviolet stimulation without treatment of the test substance. The amount of ROS was determined by reference to Tan's method of measuring the fluorescence of DCF-DA (dichlorofluorescin diacetate) oxidized by ROS (Tan et al., 1998, J. Cell Biol. Vol. 141, pp1423-1432) The ratio of the test substance to the ROS of the control group not treated with ultraviolet light was calculated and shown in Table 1 below.

Test substance UVB 30 mJ / cm ² Time elapsed after investigation 0hr 2 hr 3hr No treatment 100 244 287 UVB + no treatment 100 325 381 UVB + compound K 0.1 μM 100 324 379 UVB + compound K 1 μM 100 322 373 UVB + compound K 2 μM 100 319 366 UVB + compound K 4 μM 100 313 360 UVB + compound K 5 μM 100 309 353 UVB + compound K 20 μM 100 294 341 UVB + picronoside A 10 μM 100 315 358 UVB + picronoside A 100 μM 100 304 337 UVB + picronoside A 1000 μM 100 291 314

From the results shown in the above Table 1, it can be seen that Compound K and Pycryonoside A do not effectively inhibit the production of ROS, which is known to cause skin cell damage by ultraviolet rays, at a low concentration, and the antioxidant efficacy does not reach a desired level .

Furthermore, in order to confirm whether the compound K and picronoside A exhibited a synergistic effect on ROS generation inhibition, Compound K standard solution of Reference Example 3 (concentration: 20 μM, 5 μM, 4 μM, 2 μM, 1 μM And 0.1 .mu.M) and 100 .mu.M picronoside A standard solution, and the amount of reactive oxygen species (ROS) increased by ultraviolet stimulation was determined by the same method as above. The results are shown in Table 2 below.

Compound K concentration UVB 30 mJ / cm ² Time elapsed after investigation 0hr 2 hr 3hr Picronoside A 100 μM 0.1 μM 100 311 343 1 μM 100 305 334 2 [mu] M 100 261 298 4 μM 100 252 291 5 [mu] M 100 251 291 20 μM 100 250 289

From the results shown in Table 2, it can be confirmed that when Compound K and picronoside A are used in combination, the production of ROS is effectively suppressed even at a low concentration, and excellent antioxidative effects are exhibited.

In addition, when the concentration of Compound K was less than 2 μM, the desired degree of antioxidative effect did not appear. When the concentration of Compound K was more than 4 μM, It can be confirmed that the degree of increase in the antioxidant effect is weak. Therefore, it can be seen from the above results that the optimum combination ratio of compound K: picronoside A is 1:25 to 1:50 based on the molar concentration.

[Test Example 2] Measurement of collagen biosynthesis efficiency of skin cells

Human fibroblast (cell line: KF-4109; available from Klebosaur) was added to a 48 well microtiter plate containing 2.5% fetal bovine serum-containing DMEM (Dulbecco's Modified Eagle's Media) 10 ⁴ after concentration to put the culture, the test substances as in reference example 3 compound K standard solution (concentration: 20μM, 5μM, 4μM, 2μM , 1μM and 0.1μM) and f Cri Ono seed of reference example 4 a standard (Concentration: 1000 [mu] M, 100 [mu] M and 10 [mu] M). For comparison, the control group did not treat the test substance. After 48 hours of incubation, the supernatant was harvested and the amount of procollagen produced using the ELISA (Takara MK101) method was quantitated. The results are shown in Table 3 below, in which the control group to which the test substance was not treated was 100, and the comparative values were calculated.

density Amount of collagen production Compound K 0.1 μM 100.9 1 μM 119.7 2 [mu] M 146.8 4 μM 157.2 5 [mu] M 157.9 20 μM 160.1 Picronoside A 10 μM 129.7 100 μM 157.6 1000 μM 170.5

From the results shown in Table 3, it can be seen that Compound K and Pycryonoside A increase collagen biosynthesis even when used at a low concentration.

Further, in order to confirm whether the compound K and picronoside A exhibited a synergistic effect on collagen biosynthesis, Compound K standard solution of Reference Example 3 (concentration: 20 μM, 5 μM, 4 μM, 2 μM, 1 μM and 0.1 μM) and 100 μM picronoside A standard solution, and the amount of procollagen produced was determined by the same method as described above. The results are shown in Table 4 below.

Compound K concentration Amount of collagen production Picronoside A 100 μM 0.1 μM 155.3 1 μM 175.8 2 [mu] M 207.6 4 μM 218.9 5 [mu] M 212.7 20 μM 211.5

From the results in Table 4, it can be seen that when the compound K and picronoside A are used in combination, collagen biosynthesis is increased even at a low concentration.

In the case where the concentration of Compound K was less than 2 μM or more than 4 μM in combination with 100 μM of picronoside A, no synergistic effect was observed according to the combination, but when the concentration of the compound K was 2 to 4 μM, It can be confirmed that collagen biosynthesis can be remarkably increased. Therefore, it can be seen from the above results that the optimum combination ratio of compound K: picronoside A is 1:25 to 1:50 based on the molar concentration.

[Reference Example 5] Preparation of Examples 1 to 4 and Comparative Examples 1 to 4

The nutritional creams of Examples 1 to 4 and Comparative Examples 1 to 4 were prepared in a conventional manner according to the composition of the following Table 5 (unit: wt%).

Compounding ingredient
(Content:% by weight) Example 1 Example 2 Example 3 Example 4 Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Purified water To 100 To 100 To 100 To 100 To 100 To 100 To 100 To 100 Compound K 0.28 0.24 0.18 0.15 0.15 0.28 - - Picronoside A 4.22 4.26 4.32 4.35 - - 4.22 4.35 Vegetable hydrogenated oil 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 Stearic acid 0.60 0.60 0.60 0.60 0.60 0.60 0.60 0.60 Glycerol stearate 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Stearyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 Polyglyceryl-10pentastearate and behenyl alcohol and sodium stearoyl lactylate 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Arachidyl behenyl alcohol and arachidyl glucoside 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Cetylaryl Alcohol and Cetearyl Glucose Side 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 PEG-100 Stearate & Glycerololate & Propylene Glycol 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 Caprylic / capric triglyceride 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 Cyclone methicone 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6.0 Preservative, incense Suitable amount Suitable amount Suitable amount Suitable amount Suitable amount Suitable amount Suitable amount Suitable amount Triethanolamine 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1

[Test Example 3] Wrinkle improvement effect in human

In order to confirm the effect of improving the wrinkles in human by the composition of the present invention, the following evaluations were made using the above-described Examples 1 to 4 and Comparative Examples 1 to 4.

Eighty healthy women in their thirties were divided into eight groups of Examples 1 to 4 and Comparative Examples 1 to 4, respectively, and the nutrient cream was applied once a day for eight weeks to the face. Then, the replicas were removed using silicone to remove wrinkles The state was measured with a visiometer (SV600, Courage + Khazaka electronic GmbH, Germany) and the images were analyzed. The results are shown in Table 6 below by calculating the average of the parameter values after 8 weeks minus the pre-application parameter values.

Clinical results after 8 weeks of use R1 R2 R3 R4 R5 Example 1 -0.22 -0.20 -0.14 -0.05 -0.04 Example 2 -0.22 -0.22 -0.15 -0.05 -0.04 Example 3 -0.23 -0.22 -0.16 -0.06 -0.05 Example 4 -0.24 -0.23 -0.17 -0.06 -0.06 Comparative Example 1 -0.13 -0.14 -0.10 -0.04 -0.03 Comparative Example 2 -0.15 -0.15 -0.12 -0.05 -0.05 Comparative Example 3 -0.10 -0.09 -0.06 -0.02 -0.02 Comparative Example 4 -0.11 -0.10 -0.07 -0.03 -0.02 * R1: Difference between the maximum value and the minimum value of the contour line
R2: The wrinkle contour line is arbitrarily divided into 5 squares, and the average of R1 values
R3: Maximum value of R1 divided by 5
R4: Average value obtained by subtracting the value of each apex and valley from the baseline of the wrinkle contour line
R5: Difference between the baseline of the wrinkle contour line minus the contour of each wrinkle

As shown in Table 6, the external preparation compositions of Examples 1 to 4 using Compound K and Pycryonoside A in combination of a certain component ratio according to the present invention show excellent skin wrinkle improving effect.

[Test Example 4] Measurement of skin elasticity improvement in human body

In order to confirm the skin elasticity improvement effect in human by the composition of the present invention, the following evaluations were carried out using the above-mentioned Examples 1 to 4 and Comparative Examples 1 to 4.

80 healthy women over 30 years old were divided into eight groups of Examples 1 to 4 and Comparative Examples 1 to 4, respectively, under conditions of a temperature of 24 to 26 DEG C and a humidity of 75%, and the nutritional cream was applied twice daily for 12 weeks to the face And skin elasticity was measured using a skin elasticity meter (Cutometer SEM 575, C + K Electronic Co., Germany). The results are shown in Table 7. The results in Table 7 are expressed as the value of? R8 of the skin elasticity meter (Cutometer SEM 575), and the value of R8 indicates the property of viscoelasticity.

Application group Skin elasticity effect Example 1 0.38 Example 2 0.39 Example 3 0.42 Example 4 0.43 Comparative Example 1 0.28 Comparative Example 2 0.29 Comparative Example 3 0.30 Comparative Example 4 0.32

As shown in Table 7, the external preparation compositions of Examples 1 to 4, in which the compound K and the picronoside A were combined in a constant component ratio according to the present invention, were compared with the comparative examples containing only the compound K or picronoside A And the skin elasticity of the composition of the present invention is very effective for improving skin elasticity.

On the other hand, at the end of the test, subjects were asked to fill out questionnaires and perform subjective evaluation of efficacy at the same time as the device evaluation. The results are shown in Table 8 below.

Application group Number of respondents (in) Very good Good usually Inadequate Example 1 3 4 2 One Example 2 3 5 One One Example 3 3 6 One 0 Example 4 4 5 One 0 Comparative Example 1 0 One 4 5 Comparative Example 2 0 One 5 4 Comparative Example 3 0 2 5 3 Comparative Example 4 0 2 4 4

As shown in Table 8, the users who applied Comparative Examples 1 to 4 did not feel the skin elasticity improvement effect through the questionnaire, whereas the users who applied the compositions according to the present invention, Examples 1 to 4, Can be seen to be highly improved.

[Formulation Example 1] Lotion

Lotions are prepared according to a conventional method with the composition shown in Table 9 below.

Content (% by weight) Compound K 0.08 Picronoside A 2.42 glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinyl polymer 0.1 PEG 12 nonyl phenyl ether 0.2 Polysorbate 80 0.4 ethanol 10.0 Triethanolamine 0.1 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 2] Nourishing cream

Nutritive creams are prepared according to the usual methods with the compositions shown in Table 10 below.

Content (% by weight) Compound K 0.08 Picronoside A 2.42 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 PEG 60 hardened castor oil 2.0 Liquid paraffin 10.0 Squalane 5.0 Caprylic / caproic triglyceride 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 3] Massage cream

A massage cream is prepared according to a conventional method with the composition shown in Table 11 below.

Content (% by weight) Compound K 0.08 Picronoside A 2.42 Wax 10.0 Polysorbate 60 1.5 PEG 60 hardened castor oil 2.0 Sorbitan sesquioleate 0.8 Liquid paraffin 40.0 Squalane 5.0 Caprylic / capric triglyceride 4.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 4] Pack

A pack is prepared according to a conventional method with the composition shown in Table 12 below.

Content (% by weight) Compound K 0.08 Picronoside A 2.42 Polyvinyl alcohol 13.0 Sodium carboxymethylcellulose 0.2 glycerin 5.0 Allantoin 0.1 ethanol 6.0 PEG 12 nonyl phenyl ether 0.3 Polysorbate 60 0.3 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 5] Gel

A gel is prepared according to a conventional method with the composition shown in Table 13 below.

Content (% by weight) Compound K 0.05 Picronoside A 1.45 Ethylenediamine sodium acetate 0.05 glycerin 5.0 Carboxyvinyl polymer 0.3 ethanol 5.0 PEG 60 hardened castor oil 0.5 Triethanolamine 0.3 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 6] Ointment

Ointments were prepared in a conventional manner at the compositions listed in Table 14 below.

Content (% by weight) Compound K 0.05 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester Acetic acid 1.45 glycerin 8.0 Butylene glycol 4.0 Liquid paraffin 15.0 Beta Glucan 7.0 Carbomer 0.1 Caprylic / capric triglyceride 3.0 Squalane 1.0 Cetearyl glucoside 1.5 Sorbitan stearate 0.4 Cetearyl alcohol 1.0 Wax 4.0 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 7] Soft capsule

Compound K (0.08 mg), picronoside A (2.42 mg), vitamin C (2.5 mg), palm oil (2 mg), palm kernel oil (8 mg), yellow radish powder (4 mg) and lecithin (6 mg) were mixed in a conventional manner to prepare 400 mg of each capsule Respectively.

[Formulation Example 8] Tablets

The granules were formed by mixing 0.08 mg of compound K, 2.42 mg of picronoside A, 2.5 mg of vitamin C, 100 mg of glucose, 96 mg of starch and 4 mg of magnesium stearate and 40 mg of ethanol was added thereto, followed by drying at 60 ° C, And then the tablet was tableted.

[Formulation Example 9]

The granules were formed by mixing Compound K (4.9 mg), Pycryonoside A (145.1 mg), Vitamin C (150 mg), glucose (100 mg) and starch (600 mg) and 30% ethanol (100 mg) Lt; / RTI > The final weight of the contents was 1 g.

[Formulation Example 10]

0.042 mg of Compound K, 2.42 mg of picronoside A, 2.5 mg of vitamin C, 10 g of glucose, 2 g of citric acid and 187.8 g of purified water were mixed and filled in a bottle. The final volume of the contents was adjusted to 200 ml.

While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. something to do. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims (5)

A compound K represented by the following formula 1; And a picronoside A represented by the following formula (2) as an active ingredient,
The compound K is contained in an amount of 0.002 to 1% by weight based on the total weight of the composition,
The picronoside A is contained in an amount of 0.03 to 30% by weight based on the total weight of the composition,
Wherein the content ratio of the compound K to the picrionocide A is 1:25 to 1:50 in molar ratio.
[Chemical Formula 1]

(2)

The composition for external application for skin according to claim 1, wherein the composition is for antioxidation. The composition for external application for skin according to claim 1, wherein the composition is for promoting collagen synthesis. The composition for external application for skin according to claim 1, wherein the composition is for improving skin elasticity. The composition for external application for skin according to claim 1, wherein the composition is for improving skin wrinkles.